CAMBRIDGE, United Kingdom and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) — DIOSynVax, a clinical-stage biotechnology company at the forefront of developing safe, innovative, broadly protective vaccines presented its unique broad-based vaccine technology at the London Stock Exchange sponsored by Venture Capital Unit, Department for Business & Trade at an invitation-only, investor-only Health Tech event.
The Company’s Next-Generation Influenza portfolio including pan-Bird Flu (H5Nx) and Supra-seasonal vaccines have now demonstrated efficacy and safety in animal models including Ferrets and are both ready for human trials. The company’s vaccine antigen technology “Digital Immune Optimized Synthetic Vaccine” (DIOSynVax) is strategically positioned to leverage AI to rapidly advance safer and stronger vaccines…